Epalrestat (Standard)

Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy[1][2][3].

82159-09-9

ONO2235 (Standard)

12352005

Aldose Reductase; Reference Standards

Reference Standards

Metabolic Enzyme/Protease; Others

Cancer; Metabolic Disease; Inflammation/Immunology

https://www.medchemexpress.com/epalrestat-standard.html

90.000000

O=C(O)CN(C/1=O)C(SC1=C/C(C)=C/C2=CC=CC=C2)=S

C15H13NO3S2

319.40

[1]Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28 (5) : p. 646-55.|[2]Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42 (8) : p. 655-64.|[3]Hotta, N., et al., Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications, 1996. 10 (3) : p. 168-72.|[4]He J, et al. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation. Acta Pharmacol Sin. 2019 Jan;40 (1) :86-97.|[5]Sato K, et al. Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation. Redox Biol. 2013 Nov 19;2:15-21.|[6]Li QR, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. Neural Regen Res. 2016 Feb;11 (2) :345-51.|[7]Zhang T, et al. The Aldose Reductase Inhibitor Epalrestat Maintains Blood-Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia. Mol Neurobiol. 2023 Jul;60 (7) :3741-3757.

Blue Ice

-20°C, 3 years (Powder)